Back to Search
Start Over
A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection
- Source :
- Vaccine. 39(40)
- Publication Year :
- 2021
-
Abstract
- Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted disease that affects approximately 500 million individuals globally. There is currently no approved vaccine to prevent HSV-2 infection. EXCT4 is a truncated form of the mature glycoprotein G-2 (mgG-2) that unlike full mature form is secreted by expressing cells enabling it to be rapidly scaled up for production. The current study examined whether EXCT4 immunity in mice could be further enhanced through use of adjuvants. EXCT4 formulated with Advax-CpG adjuvant induced a strong Th1-type immune response characterized by interferon gamma (IFN-γ) and protected animals against a lethal genital challenge with HSV-2. This response was associated with reduced viral load in vaginal washes, spinal cord, and dorsal root ganglia. Together the results provide proof of concept that EXCT4 formulated with Advax-CpG adjuvant is a promising HSV-2 vaccine candidate warranting further investigation.
- Subjects :
- Sexually transmitted disease
CpG Oligodeoxynucleotide
medicine.medical_treatment
Herpesvirus 2, Human
Biology
medicine.disease_cause
Virus
Mice
Immune system
Viral Envelope Proteins
Immunity
medicine
Animals
Vaccines
Herpes Genitalis
General Veterinary
General Immunology and Microbiology
Public Health, Environmental and Occupational Health
Inulin
Virology
Infectious Diseases
Herpes simplex virus
Molecular Medicine
Female
Adjuvant
Viral load
Subjects
Details
- ISSN :
- 18732518
- Volume :
- 39
- Issue :
- 40
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....1d7da9117c9703e7d84283490263a508